Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Mineralys said the NDA for Lorundrostat was submitted late last year and the PDUFA date was set in March, with management still feeling positive about approval. The company is building out market access and medical affairs teams in preparation for a potential U.S. launch targeting up to 20 million patients with hypertension-related cardiovascular risk. The discussion also highlighted its recently announced IP deal with Tanabe, underscoring pipeline and commercialization readiness.

Analysis

The core market implication is not simply binary approval risk; it is that MLYS is transitioning from a clinical/program story into a commercialization and reimbursement execution story, which typically re-rates volatility rather than removes it. If the asset clears FDA, the first-order pop is likely less important than the second-order question of how quickly payers accept a premium chronic-care hypertension therapy in a market dominated by cheap generics and entrenched ARBs/diuretics. That creates a classic launch setup where the stock can look cheap on approval, then get repriced on early access data, formulary wins, and physician adoption velocity over the next 2-4 quarters.

The Tanabe IP move matters because it reduces a hidden overhang: even when a product has strong efficacy, fragmented rights or royalty leakage can cap long-duration economics and complicate strategic optionality. Consolidating rights should improve takeout value and makes the asset more legible to larger cardio/metabolic players that prefer clean IP and global controllability; the second-order beneficiary is any potential acquirer seeking to build a renal/cardiovascular franchise, while competitors with follow-on aldosterone or BP assets may see a higher bar for differentiation if MLYS can lock in first-mover perception.

The main tail risk is not approval denial alone; it is a delayed label, onerous post-marketing requirements, or payer resistance that turns a strong science story into a slow-burn commercial disappointment. In that scenario, the stock could re-rate sharply lower even after an initial positive catalyst, because launch expectations are already being pulled forward into 2026 and the street may be underpricing the time needed to convert prescribers and access teams into net prescriptions. The contrarian view is that the opportunity may be underappreciated if lorundrostat becomes one of the few differentiated therapies with both blood-pressure reduction and CV-risk framing, which would make the revenue curve much more durable than a simple niche specialty launch.

Key Decisions for Investors

• Long MLYS into the PDUFA window, but size as a catalyst trade rather than a core position; use a 6-12 month horizon and assume elevated binary volatility.
• If approved, add on initial post-event weakness only if management commentary suggests payer coverage and launch readiness are intact; risk/reward improves after the first de-risking move rather than before it.
• Consider a call-spread structure on MLYS for the approval-to-launch window to express upside while limiting downside if the FDA outcome or label is less favorable than expected.
• Pair long MLYS vs short a basket of lower-differentiation hypertension/adjacent cardio names if the market starts pricing in a clean launch premium; the thesis is that clean IP plus a differentiated mechanism should outperform me-too exposure.
• Take profits aggressively if approval is followed by a sharp gap-up without evidence of reimbursement traction; the stock’s next leg will likely depend on access data, not the headline decision.